Beacon Investment Advisory Services Inc. Purchases 10,226 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Beacon Investment Advisory Services Inc. increased its stake in Gilead Sciences by 11.8%, owning 96,887 shares valued at approximately $10.74 million after acquiring an additional 10,226 shares in the second quarter.
• The biopharmaceutical company reported quarterly earnings of $2.01 per share, surpassing analysts' expectations, with a revenue of $7.08 billion for the period, indicating a year-over-year increase of 1.4%.
• Gilead Sciences declared a quarterly dividend of $0.79 per share, which will be paid on September 29th, representing an annual yield of 2.8%.

Beacon Investment Advisory Services Inc. raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 96,887 shares of the biopharmaceutical company's stock after purchasing an additional 10,226 shares during the period. Beacon Investment Advisory Services Inc.'s holdings in Gilead Sciences were worth $10,742,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences in the first quarter worth $25,000. Activest Wealth Management boosted its holdings in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 227 shares during the period. Goodman Advisory Group LLC bought a new position in shares of Gilead Sciences in the first quarter worth $29,000. Colonial Trust Advisors boosted its holdings in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 213 shares during the period. Finally, Core Alternative Capital boosted its holdings in shares of Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 241 shares during the period. 83.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on GILD shares. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective on the stock in a research report on Tuesday, August 19th. Royal Bank Of Canada increased their price objective on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Finally, Rothschild & Co Redburn increased their price objective on Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a research report on Friday, September 12th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $117.17.

Gilead Sciences Trading Down 0.6%

NASDAQ GILD opened at $113.67 on Thursday. The stock's 50-day simple moving average is $114.29 and its two-hundred day simple moving average is $110.01. Gilead Sciences, Inc. has a twelve month low of $81.83 and a twelve month high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $141.04 billion, a price-to-earnings ratio of 22.64, a PEG ratio of 0.78 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter last year, the business posted $2.01 earnings per share. The company's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the sale, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the transaction, the insider owned 113,193 shares in the company, valued at approximately $12,855,329.01. This represents a 2.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $9,390,030 over the last 90 days. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.